Abstract:Clinical trials suggested that sentinel lymph node (SLN) biopsy (SLNB) alone provided non-inferior survival than further axillary lymph node dissection (ALND) among breast cancer patients with negative SLNs. However, the long-term outcomes of these two surgical approaches in breast cancer patients with pathologically negative lymph nodes (pN0) remain uncertain. We performed a population-based study using the Surveillance, Epidemiology, and End Results (SEER) 18-registry database. We included patients who received a diagnosis between 2000 and 2015 of pathological stage T1-2N0M0 breast cancer and adopted a breast-conserving surgery (BCS) or mastectomy. Patients were considered to have undergone an SLNB alone if they had ≤ 5 examined lymph nodes (ELNs), and ALND if they had ≥ 10 ELNs, while others were excluded given an equivocate lymph node surgery approach. Outcomes included overall survival (OS) and breast cancer-specific survival (BCSS). Propensity-score analyses by weighting and matching and multivariable Cox regression were performed to minimize treatment selection bias. We included 309430 patients, 253501 (81.9%) underwent SLNB and 55929 (18.1%) underwent ALND. The median follow-up time in the weighted cohort was 122 months for SLNB group and 119 months for ALND group, respectively. ALND was associated with significantly lower OS (hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.10-1.16; 10-year OS, 78.2%; 95% CI, 77.8%-78.6%) and lower BCSS (HR, 1.16; 95% CI, 1.10-1.22; 10-year BCSS, 93.4%; 95% CI, 93.1%-93.6%) compared with SLNB alone (10-year OS, 80.4%; 95% CI, 80.2%-80.6%; 10-year BCSS, 94.2%; 95% CI, 94.1%-94.3%). Both the propensity score-matching model and multivariable Cox model demonstrated a survival benefit for SLNB group compared with ALND group. Subgroup analyses for key variables did not change these findings. SLNB was associated with a significantly lower risk of death than ALND in breast cancer patients with pN0 disease. Our study first provides evidence of survival benefit, supporting that SLNB alone is a better option for patients with no metastatic lymph nodes identified after breast cancer operation.

The clinical application of sentinel lymph node biopsy replacing axillary lymph node dissection in breast cancer

High Risk For Non-Sentinel Node Metastasis In Breast Cancer Patients With Sentinel Node Metastases

Study of sentinel lymph node biopsy in directing selective axillary lymph node dissection in patients receiving breast-conserving therapy

Sentinel Node Biopsy and Quality of Life Measures in a Chinese Population

Clinical Significance of Sentinel Lymph Node Biopsy in Breast Reservation and Axillary Reservation in Patients with Breast Cancer

[Detection of Sentinel Lymph Node in Patients with Early Stage Breast Cancer].

Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial

Sentinel lymph node biopsy (SLNB) vs. axillary lymph node dissection (ALND) in the current surgical treatment of early stage breast cancer

Research Progress of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy for Breast Cancer

Clinical Study of Sentinel Lymph Node Biopsy in Patients with Stage I、II Breast Cancer

Evaluation on feasibility of sentinel lymph node biopsy in breast cancer patients after neoadj uvant chemotherapy

Clinical research in endoscopically axillary sentinel lymph node biopsy for breast cancer

Clep_a_264349 917..924

136P Assessment of Sentinel Lymph Node Biopsy Versus Axillary Lymph Node Dissection on Long-Term Survival in Breast Cancer Patients with Pathologically Negative Lymph Node

Current studies and evaluations of sentinel lymph node biopsy for breast cancer

Axillary Dissection vs. no Axillary Dissection in Breast Cancer Patients With Positive Sentinel Lymph Node: A Single Institution Experience

Axillary Surgical Attitude Changing with Retrospective Application of ACOSOG Z0011 Eligible Criteria: An Institutional Evaluation.

Sentinel lymph node biopsy in patients with operable breast cancer after neoadjuvant systemic therapy

De-Escalation of Axillary Surgery in Clinically Node-Positive Breast Cancer Patients Treated with Neoadjuvant Therapy: Comparative Long-Term Outcomes of Sentinel Lymph Node Biopsy versus Axillary Lymph Node Dissection

[Our experience of the clinical application of sentinel node biopsy in breast cancer]

Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study